Related Experiment Video
Updated: Jul 24, 2025
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.1K
Tofacitinib in pyoderma gangrenosum - A case series
Vanitha Agrahara Sathyanarayana1, Debaditya Roy2, Bhavya Nagaraju3
1Department of Rheumatology, Divisha Arthritis and Medical Center, Bangalore, India.
International Journal of Rheumatic Diseases
|July 3, 2023
Summary
Pyoderma gangrenosum (PG) is a rare skin condition. Tofacitinib, a JAK/STAT inhibitor, successfully treated three PG cases, preventing relapse during follow-up.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Pyoderma gangrenosum (PG) is a rare, autoinflammatory neutrophilic dermatosis.
- Characterized by non-infective, non-neoplastic skin ulcerations, often without primary vasculitis.
- PG lesions frequently relapse, necessitating prolonged treatments, including steroids.
Observation:
- Three cases of biopsy-proven Pyoderma gangrenosum were identified.
- These patients presented with severe, relapsing skin ulcerations.
- Conventional treatments were considered, but alternative options were explored due to disease persistence.
Findings:
- Successful treatment of three isolated Pyoderma gangrenosum cases with Tofacitinib.
- Tofacitinib, a Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway inhibitor, was utilized.
- No relapse of Pyoderma gangrenosum lesions was observed during the follow-up period.
Implications:
- Tofacitinib shows promise as an effective treatment for Pyoderma gangrenosum.
- Targeting the JAK/STAT pathway may offer a new therapeutic strategy for this condition.
- Further evidence-based studies are warranted to confirm Tofacitinib's efficacy and safety in larger PG cohorts.
More Related Videos
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
175
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
175
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
200
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
200
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
156
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
156
01:20The JAK-STAT Signaling Pathway
9.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.0K
01:30Inflammatory Bowel Disease II: Crohn's Disease
299
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
299
01:29Drugs for Treatment of Ulcerative Colitis in IBD
175
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
175